340 related articles for article (PubMed ID: 23301549)
1. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
Herbers U; Amini-Bavil-Olyaee S; Mueller A; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
[TBL] [Abstract][Full Text] [Related]
2. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
3. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Sheldon J; Luedde T; Trautwein C; Tacke F
Hepatology; 2009 Apr; 49(4):1158-65. PubMed ID: 19263474
[TBL] [Abstract][Full Text] [Related]
4. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
Tacke F; Gehrke C; Luedde T; Heim A; Manns MP; Trautwein C
J Virol; 2004 Aug; 78(16):8524-35. PubMed ID: 15280461
[TBL] [Abstract][Full Text] [Related]
5. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Zhu Y; Curtis M; Borroto-Esoda K
Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
[TBL] [Abstract][Full Text] [Related]
6. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
Chen RY; Edwards R; Shaw T; Colledge D; Delaney WE; Isom H; Bowden S; Desmond P; Locarnini SA
Hepatology; 2003 Jan; 37(1):27-35. PubMed ID: 12500185
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
Qi X; Xiong S; Yang H; Miller M; Delaney WE
Antivir Ther; 2007; 12(3):355-62. PubMed ID: 17591025
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
Amini-Bavil-Olyaee S; Herbers U; Mohebbi SR; Sabahi F; Zali MR; Luedde T; Trautwein C; Tacke F
J Hepatol; 2009 Oct; 51(4):647-54. PubMed ID: 19586679
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
[TBL] [Abstract][Full Text] [Related]
11. Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.
Lee JH; Hong SP; Jang ES; Park SJ; Hwang SG; Kang SK; Jeong SH
J Med Virol; 2015 Jun; 87(6):993-8. PubMed ID: 25712861
[TBL] [Abstract][Full Text] [Related]
12. Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy.
van Bömmel F; Trojan J; Deterding K; Wedemeyer H; Wasmuth HE; Hüppe D; Möller B; Bock FJ; Feucht HH; Berg T
Antivir Ther; 2012; 17(6):1049-58. PubMed ID: 22892524
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
Svarovskaia ES; Curtis M; Zhu Y; Borroto-Esoda K; Miller MD; Berg T; Lavocat F; Zoulim F; Kitrinos KM
J Viral Hepat; 2013 Feb; 20(2):131-40. PubMed ID: 23301548
[TBL] [Abstract][Full Text] [Related]
14. Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in Lamivudine-resistant chronic hepatitis B patients.
Song BC; Cui XJ; Shin JW; Park NH; Cho YK; Song HJ; Hyun S; Jeong SU; Choi EK; Kim HU
Intervirology; 2010; 53(4):203-10. PubMed ID: 20332649
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
[TBL] [Abstract][Full Text] [Related]
16. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
Wang Y; Wei L; Jiang D; Cong X; Fei R; Chen H; Xiao J; Wang Y
Antiviral Res; 2007 Aug; 75(2):139-45. PubMed ID: 17397939
[TBL] [Abstract][Full Text] [Related]
17. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
Chang UI; Lee YC; Wie SH; Jang JW; Bae SH; Choi JY; Yang JM; Yoon SK; Sun HS
J Med Virol; 2007 Jul; 79(7):902-10. PubMed ID: 17516533
[TBL] [Abstract][Full Text] [Related]
18. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
Liu Y; Liu W; Li X; Xu Z; Wang X; Li C; Chen L; Xin S; Xu D
Antivir Ther; 2014; 19(6):551-8. PubMed ID: 24710668
[TBL] [Abstract][Full Text] [Related]
19. HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D.
Liu Y; Miller MD; Kitrinos KM
Liver Int; 2014 Aug; 34(7):1025-32. PubMed ID: 24118725
[TBL] [Abstract][Full Text] [Related]
20. Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.
Amini-Bavil-Olyaee S; Vucur M; Luedde T; Trautwein C; Tacke F
J Virol; 2010 Jan; 84(2):1026-33. PubMed ID: 19889778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
